ONP-002 Advances Toward Phase IIa Concussion Trial with Strengthened Financial Foundation and Industry MomentumSARASOTA, Fla.

If we want to turn these short-term gains into sustainable change, we must fully unleash the potential of methadone-assisted ...

Non-drug approaches can help people cope with stress and despair, says an expert. Read more at straitstimes.com.

The current state of treatment for geographic atrophy is marked by two approved therapies that slow GA progression: ...

BOSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology ...

Varied approaches to remote patient monitoring are in development to close care gaps between patients and rheumatologists, ...

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A ...

Philip Taylor; Investor Relations; Pulse Biosciences Inc. Paul Laviolette; Co-Chairman of the Board, President, Chief Executive Officer; Pulse Biosciences Inc. Jon S ...

Full-year results and business updateClinical proof of principle obtained in Phase I adjuvant head and neck cancer trial with individualized ...

On track for multiple clinical updates through mid-2026, including further progress from two ongoing clinical programs and initiation of therapeutic dosing of potential new medicine, all based on our ...

Eleonora Teplinsky, MD, a medical oncologist specializing in breast and gynecologic cancers, has seen unregulated and ...

With the newly completed OT-101 and IL-2 Phase 1 trial, Oncotelic is poised to begin further combination trials to determine the added efficacy of OT-101, IL-2, and CKIs in solid tumors such as lung ...